1229018-87-4
Chemical Structure
TPN171
- CAS No.: 1229018-87-4
- Formula:C24H35N5O3
- Molecular Weight:441.57
IUPAC Name: N-(3-(4,5-diethyl-6-oxo-1,6-dihydropyrimidin-2-yl)-4-propoxyphenyl)-2-(4-methylpiperazin-1-yl)acetamide
InChIKey: PIOIVHHIGWTEJQ-UHFFFAOYSA-N
SMILES: CCCOC1=C(C2=NC(CC)=C(CC)C(N2)=O)C=C(NC(CN3CCN(C)CC3)=O)C=C1
Biological Activity: TPN171 is an orally active and selective PDE5 inhibitor with an IC50 of 0.62 nM. TPN171 elevates cGMP and enhances NO-mediated vasodilation and smooth muscle relaxation. TPN171 exhibits concentration-dependent inhibition of OCT2, MATE1, and MATE2-K. TPN171 is a substrate of CYP3A4. TPN171 can be used for research on pulmonary arterial hypertension and erectile dysfunction[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
TPN171 | 98.10% | TPN171 is an orally active and selective PDE5 inhibitor with an IC50 of 0.62 nM. TPN171 elevates cGMP and enhances NO-mediated vasodilation and smooth muscle relaxation. TPN171 exhibits concentration-dependent inhibition of OCT2, MATE1, and MATE2-K. TPN171 is a substrate of CYP3A4. TPN171 can be used for research on pulmonary arterial hypertension and erectile dysfunction. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.56
HY-131101RNor-Acetildenafil (Standard) -
Similarity Score 0.54
HY-13927RAcetildenafil (Standard) -
Similarity Score 0.52
HY-100650Carbodenafil -
Similarity Score 0.50
HY-W587881Acetylvardenafil -
Similarity Score 0.50
HY-117882Piperiacetildenafil -
Similarity Score 0.47
HY-119316ACM-545 -
Similarity Score 0.47
HY-133106Sildenafil impurity 5 -
Similarity Score 0.47
HY-138127Gendenafil -
Similarity Score 0.47
HY-W585919Sildenafil impurity 12 -
Explore the MedChemAI to find more analogs
References
- [1]. Yang Y, et al. Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension. Acta Pharmaceutica Sinica B. 2020 Dec 1;10(12):2339-47. [Content Brief]
- [2]. Zhang T, et al. Discovery of evodiamine derivatives as highly selective PDE5 inhibitors targeting a unique allosteric pocket. Journal of medicinal chemistry. 2020 Aug 14;63(17):9828-37.
- [3]. Wang Z, et al. Pharmacokinetics-driven optimization of 4 (3 H)-pyrimidinones as phosphodiesterase type 5 inhibitors leading to TPN171, a clinical candidate for the treatment of pulmonary arterial hypertension. Journal of Medicinal Chemistry. 2019 Apr 25;62(10):4979-90. [Content Brief]
- [4]. Bukowska B, et al. Ethanol as a Modifier of Drug Toxicity in Humans: Pathways of Toxicity and Organ-Level Consequences. International journal of molecular sciences. 2026 Jul 14;27(14):6270.
- [5]. Tian G, et al. A Physiologically Based Pharmacokinetic Model to Predict Potential Drug–Drug Interactions of TPN171, a Novel Phosphodiesterase Type 5 Inhibitor. CPT: Pharmacometrics & Systems Pharmacology. 2026 Aug;15(8):e70298.
